TANDEM DIABETES CARE INC (TNDM) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:TNDM • US8753722037

18.86 USD
-0.13 (-0.68%)
Last: Feb 5, 2026, 11:49 AM

TNDM Key Statistics, Chart & Performance

Key Statistics
Market Cap1.28B
Revenue(TTM)1.01B
Net Income(TTM)-203.37M
Shares67.80M
Float67.07M
52 Week High36.59
52 Week Low9.98
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-1.44
PEN/A
Fwd PEN/A
Earnings (Next)02-19
IPO2013-11-13
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
TNDM short term performance overview.The bars show the price performance of TNDM in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

TNDM long term performance overview.The bars show the price performance of TNDM in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of TNDM is 18.86 USD. In the past month the price decreased by -19.33%. In the past year, price decreased by -47.4%.

TANDEM DIABETES CARE INC / TNDM Daily stock chart

TNDM Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to TNDM. When comparing the yearly performance of all stocks, TNDM is a bad performer in the overall market: 82.12% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

TNDM Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to TNDM. Both the profitability and financial health of TNDM have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TNDM Financial Highlights

Over the last trailing twelve months TNDM reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS increased by 16.53% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -23.25%
ROE -152.95%
Debt/Equity 2.37
Chartmill High Growth Momentum
EPS Q2Q%11.43%
Sales Q2Q%2.17%
EPS 1Y (TTM)16.53%
Revenue 1Y (TTM)17.87%

TNDM Forecast & Estimates

30 analysts have analysed TNDM and the average price target is 23.97 USD. This implies a price increase of 27.09% is expected in the next year compared to the current price of 18.86.

For the next year, analysts expect an EPS growth of -29.52% and a revenue growth 10.11% for TNDM


Analysts
Analysts72.67
Price Target23.97 (27.09%)
EPS Next Y-29.52%
Revenue Next Year10.11%

TNDM Ownership

Ownership
Inst Owners115.78%
Ins Owners0.72%
Short Float %13.43%
Short Ratio5.61

TNDM Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABT ABBOTT LABORATORIES19.01188.146B
ISRG INTUITIVE SURGICAL INC48.72169.625B
SYK STRYKER CORP24.13137.924B
BSX BOSTON SCIENTIFIC CORP22.06111.924B
BDX BECTON DICKINSON AND CO13.7559.33B
IDXX IDEXX LABORATORIES INC43.5351.339B
EW EDWARDS LIFESCIENCES CORP26.6746.291B
RMD RESMED INC21.7738.394B
GEHC GE HEALTHCARE TECHNOLOGY16.5537.64B
DXCM DEXCOM INC27.927.621B

About TNDM

Company Profile

TNDM logo image Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. The company is headquartered in San Diego, California and currently employs 2,650 full-time employees. The company went IPO on 2013-11-13. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.

Company Info

TANDEM DIABETES CARE INC

12400 High Bluff Drive

San Diego CALIFORNIA 92121 US

CEO: John F. Sheridan

Employees: 2650

TNDM Company Website

TNDM Investor Relations

Phone: 18583666900

TANDEM DIABETES CARE INC / TNDM FAQ

What does TANDEM DIABETES CARE INC do?

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. The company is headquartered in San Diego, California and currently employs 2,650 full-time employees. The company went IPO on 2013-11-13. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.


What is the stock price of TANDEM DIABETES CARE INC today?

The current stock price of TNDM is 18.86 USD. The price decreased by -0.68% in the last trading session.


Does TANDEM DIABETES CARE INC pay dividends?

TNDM does not pay a dividend.


How is the ChartMill rating for TANDEM DIABETES CARE INC?

TNDM has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Where is TANDEM DIABETES CARE INC (TNDM) stock traded?

TNDM stock is listed on the Nasdaq exchange.


How is the market expecting TNDM stock to perform?

30 analysts have analysed TNDM and the average price target is 23.97 USD. This implies a price increase of 27.09% is expected in the next year compared to the current price of 18.86.


What is the GICS sector and industry of TNDM stock?

TANDEM DIABETES CARE INC (TNDM) operates in the Health Care sector and the Health Care Equipment & Supplies industry.